JOHNS HOPKINS CANCER REGISTRY 2009

Slides:



Advertisements
Similar presentations
Advances and Emerging Therapy for Lung Cancer
Advertisements

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
BREAST CANCER EPIDEMIOLOGY AND BREAST PHYSIOLOGY Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University.
Impact of Cancer Diagnosis and Chemotherapy on Mammography Use Xinhua Yu, M.B., Ph.D. A. Marshall McBean, M.D., M.Sc. Beth A. Virnig, Ph.D., M.P.H Division.
Prognostic factors for breast cancer survival in affluent and deprived areas Jasmina Stefoski-Mikeljevic.
Elshami M.Elamin, MD Medical Oncologist Central Care Cancer Center Wichita, KS, USA
APIII October 23, 2008 Establishing Indicators for Cancer Care: The Role of the Cancer Registry and Other Oncology Data Sources Presented by: Sharon Winters.
FEMALE BREAST CANCER JOHNS HOPKINS HOSPITAL CANCER REGISTRY Prepared by Theresa SanLorenzo-Caswell, CTR 10/03/20014.
Dr Matt Hewitt Prophylactic Bilateral Salpingoophorectomy.
Factors Associated with Bilateral vs. Unilateral Mastectomy in a Diverse, Population-based Sample of Breast Cancer Patients Sarah T. Hawley, PhD, MPH University.
Suggested guidelines for appropriate patient selection for patients undergoing Accelerated Partial Breast Irradiation at DMC. Tonya Echols Cole, MD.
First month Second Month First month Second Month Milk line remnant Milk line remnant Accessory axillary breast tissue Accessory axillary breast tissue.
Endometrial Carcinoma
THYROID CANCER JOHNS HOPKINS HOSPITAL CANCER REGISTRY Prepared by Theresa SanLorenzo-Caswell, CTR 09/02/2013.
PROSTATE CANCER JOHNS HOPKINS HOSPITAL CANCER REGISTRY Prepared by Theresa SanLorenzo-Caswell, CTR 09/01/2013.
MELANOMA JOHNS HOPKINS HOSPITAL CANCER REGISTRY Prepared by Theresa SanLorenzo-Caswell, CTR 10/16/20014.
LUNG CANCER Johns Hopkins Hospital Lung Cancer, Non-Small Cell , All Cases n=1364 Analytic - Initially Diagnosed and/or received all.
PANCREATIC CANCER JOHNS HOPKINS HOSPITAL CANCER REGISTRY 2009.
SEER Provided Data Mohammad Afnan Baqai 12/3/2009.
HER2 POSITIVE BREAST CARCINOMA IN THE PRE AND POST ADJUVANT ANTI-HER-2 THERAPY ERA: A SINGLE ACADEMIC INSTITUTION EXPERIENCE IN THE SETTING OUTSIDE OF.
Prognostic value of ER, PR, and HER2 breast cancer biomarkers and AJCC’s TNM staging system on overall survival of Caucasian females with breast cancer.
Jo Anne Zujewski, MD Clinical Investigations Branch Cancer Therapy Evaluation Program Division of Cancer Diagnosis and Treatment May 2011 The Global Burden.
THYROID CANCER JOHNS HOPKINS HOSPITAL CANCER REGISTRY Prepared by Theresa SanLorenzo-Caswell, CTR 10/16/20014.
The Inflammatory Breast Cancer Cancer Registry Paul H. Levine, M.D. Paul H. Levine, M.D. The George Washington University School of Public Health and Health.
Differential Diagnoses September 25, You are a psychologist who has been referred 5 cases from the local school district. You have been asked to.
Breast cancer affects 1 in 8 women during their lives. 1 Population Statistics.
GASTRIC CANCER JHH Johns Hopkins Hospital Gastric Cancer , All Cases n=317 Analytic - Initially Diagnosed and/or received all or.
ANALYTIC LUNG CANCER by CLASS N = 351 Class 0: Dx’d at JHH only 1: Dx’d at JHH and received all/part of 1st course tx at JHH 2: Dx’d at an outside facility.
Cancer Committee Meeting May 11, 2015 Cancer Liaison Physician Report Karen Lisa Smith MD MPH.
HEAD/NECK CARCINOMA Johns Hopkins Hospital.
Radical vs Partial Nephrectomy for treatment of renal cell carcinoma at Prince Hussein Urology Centre Dr. Mohammad Alserhan Urology specialist Prince Hussein.
Quality & Sustainability in Cancer Control: A System Performance Spotlight Report To use a hyperlink, right click on it and select ‘Open Hyperlink’, or.
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab.
Linking Electronic Health Records Across Institutions to Understand Why Women Seek Care at Multiple Sites for Breast Cancer Caroline A. Thompson, PhD,
Presented at the NAACCR Annual Conference Quebec City June 22, 2010.
Johns Hopkins Hospital Cancer Registry Melanoma
JHH Prostate Cancer Prostate Cancer Cases Diagnosed 1999 – 2004 Analytic vs. Non-Analytic n=7776 * Analytic - Initially Diagnosed and/or received.
The Role of the HCC Cancer Registry in Facilitating Cancer Research Linda Cope, CTR HCC Registry Coordinator
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Phase III MF07-01 Trial: Impact of Initial Local Resection on Stage.
What does the data tell us? Colorectal CANCER IN NEVADA
NON-SMALL CELL LUNG CANCER
Age and Racial/Ethnic Disparities in the Diagnosis of Breast Cancer in an Urban Population Joanne K. Fagan PhD, Denise Fyffe, PhD, Nadine Jenkins, CTR,
Ari Brooks, MD Cancer Surgeon, Big Data End User
Prognostic significance of tumor subtypes in male breast cancer:
Dr Amit Gupta Associate Professor Dept Of Surgery
Surgical Management of the Breast in Breast Cancer
Ductal Carcinoma (Breast Cancer)
JOHNS HOPKINS HOSPITAL CANCER REGISTRY
Presented By Deborah Schrag at 2016 ASCO Annual Meeting
Johns Hopkins Hospital Malignant and Benign Brain/CNS
Creating the perfect text…
ANALYTIC PANCREATIC CANCER by CLASS N = 369
Johns Hopkins Hospital Cancer Registry
Male and Female Reproductive Health Concerns
Marcelo Calil Instituto Brasileiro de Controle do Câncer
سرطان الثدي Breast Cancer
Dr T P E Wells 13 July 2018 Breast SSG Bath
So you have been diagnosed with breast cancer! What's next?
Program Goals. Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer.
Estimated current cancer incidence
Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study  Stephen H. Culp, Paul.
4155 primary hepatocellular carcinoma with known diagnosis month/year
Primary Cardiac Sarcoma
Data Analytics course.
OncotypeDX DCIS test use and clinical utility: A SEER population-based study Yao Yuan, PhD, MPH, Alison Van Dyke, MD, PhD, Serban Negoita, MD, DrPH & Valentina.
Martin Whiteside, DC, PhD, MSPH Director, Tennessee Cancer Registry
Nadia Howlader, PhD National Cancer Institute
Age-adjusted incidence and mortality rates by race for breast cancer (all ages, females, SEER 9 registries for , age adjusted to the 2000 United.
Principles and Practice of Radiation Therapy
Presentation transcript:

JOHNS HOPKINS CANCER REGISTRY 2009 FEMALE BREAST CANCER JOHNS HOPKINS CANCER REGISTRY 2009

ANALYTIC FEMALE BREAST CANCER 2009 by CLASS N=616 Class 0: Dx’d at JHH only 1: Dx’d at JHH and received all/part of 1st course tx at JHH 2: Dx’d at an outside facility and all/part of 1st course tx at JHH

ANALYTIC* FEMALE BREAST CANCER 2009 AGE AT DIAGNOSIS N=616 *Includes 13 class 0 cases

ANALYTIC* FEMALE BREAST CANCER 2009 by RACE N=616 *Includes 13 class 0 cases

ANALYTIC FEMALE BREAST CANCER 2009 by AJCC STAGE Class 1 & 2 N=603

ANALYTIC FEMALE BREAST CANCER 2009, CLASS 1 & 2, AJCC Stage 0, N=126 No tx (3 cases) 1 – refused all treatment, 2 – had another primary invasive primary requiring immediate treatment The pt who received surg/rad/chemo/horm had bilateral breast ca.

ANALYTIC FEMALE BREAST CANCER 2009, CLASS 1&2 AJCC Stage I N=222 Pts that had surgery and rad w/o hormone and pos er/pr 1 pt wanted to go to another med onc, no information was given to JHH on who the new doc is. 1 pt does not want hormone treatment 1 pt – hormone treatment recommended, but pt never came back to JHH to receive. 1 PT – not recommended, only had microinvasive disease, being tx for dcis, er was very low. *1 pt noncompliant **1 pt – Already being treated for another primary breast ca

ANALYTIC FEMALE BREAST CANCER 2009, CLASS 1&2 AJCC Stage II N=158

ANALYTIC FEMALE BREAST CANCER 2009, CLASS 1&2 AJCC Stage III N=76

ANALYTIC FEMALE BREAST CANCER 2009, CLASS 1&2 AJCC Stage IV N=20 1 pt didn’t get treatment

ANALYTIC FEMALE BREAST CANCER JHH OBSERVED SURVIVAL 1998-2004 by AJCC STAGE

ANALYTIC FEMALE BREAST CANCER JHH OBSERVED SURVIVAL 1998-2004 by RACE ALL STAGES

ANALYTIC FEMALE BREAST CANCER JHH OBSERVED SURVIVAL 1998-2004 by AGE AT DIAGNOSIS, ALL STAGES

ANALYTIC FEMALE BREAST CANCER OBSERVED SURVIVAL 1998-2002 by JHH vs ANALYTIC FEMALE BREAST CANCER OBSERVED SURVIVAL 1998-2002 by JHH vs. MD vs. NCDB vs. NCI ©2010 National Cancer Data Base/Commission on Cancer